{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:25Z","timestamp":1787009425860,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004726","name":"British Columbia Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The British Columbia Ministry of Health launched a Smoking Cessation Program on September 30, 2011, providing financial coverage for smoking cessation pharmacotherapies. Although pharmacotherapies have been shown to have a moderate short-term benefit as a quitting aid, substantial cardiovascular and neuropsychiatric safety concerns have been identified in adverse-reporting databases, leading to prescription label warnings by Health Canada and the U.S. Food and Drug Administration. However, recent studies indicate these warnings may be without merit. This study examined the comparative safety of medications commonly used to aid smoking cessation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims and Methods<\/jats:title>\n                    <jats:p>Population-based retrospective cohort study using B.C. administrative data to assess the relative safety between varenicline, bupropion, and nicotine replacement therapies (NRTs). The primary outcome was a composite of cardiovascular hospitalizations. Secondary outcomes included mortality, a composite of neuropsychiatric hospitalizations, and individual components of the primary outcome. Statistical analysis used propensity score-adjusted log-binomial regression models. A sensitivity analysis excluded patients with a history of cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 116 442 participants. Compared with NRT, varenicline was associated with a 10% 1-year relative risk decrease of cardiovascular hospitalization (adjusted risk ratio [RR] = 0.90, 95% confidence interval (CI): 0.82 to 1.00), a 20% 1-year relative risk decrease of neuropsychiatric hospitalization (RR: 0.80, CI: 0.7 to 0.89), and a 19% 1-year relative risk decrease of mortality (RR: 0.81, CI: 0.71 to 0.93). We found no significant association between NRT and bupropion for cardiovascular hospitalizations, neuropsychiatric hospitalizations, or mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with NRT, varenicline is associated with fewer serious adverse events and bupropion the same number of serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications<\/jats:title>\n                    <jats:p>This study addresses the need for comparative safety evidence in a real-world setting of varenicline and bupropion against an active comparator. Compared with NRT, varenicline was associated with a decreased risk of mortality, serious cardiovascular events, and neuropsychiatric events during the treatment, or shortly after the treatment, in the general population of adults seeking pharmacotherapy to aid smoking cessation. These results provide support for the removal of the varenicline boxed warning for neuropsychiatric events and add substantively to the cardiovascular safety findings of previous observational studies and randomized clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ntr\/ntaa100","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T15:12:44Z","timestamp":1590419564000},"page":"302-309","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Safety of Smoking Cessation Pharmacotherapies During a Government-Sponsored Reimbursement Program"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-5172","authenticated-orcid":false,"given":"Greg","family":"Carney","sequence":"first","affiliation":[{"name":"Therapeutics Initiative, University of British Columbia, Vancouver, BC, Canada"},{"name":"Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Maclure","sequence":"additional","affiliation":[{"name":"Therapeutics Initiative, University of British Columbia, Vancouver, BC, Canada"},{"name":"Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Malfair","sequence":"additional","affiliation":[{"name":"Lions Gate Hospital, Fraser Health Authority, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Bassett","sequence":"additional","affiliation":[{"name":"Therapeutics Initiative, University of British Columbia, Vancouver, BC, Canada"},{"name":"Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada"},{"name":"Department of Family Practice, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Wright","sequence":"additional","affiliation":[{"name":"Therapeutics Initiative, University of British Columbia, Vancouver, BC, Canada"},{"name":"Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin R","family":"Dormuth","sequence":"additional","affiliation":[{"name":"Therapeutics Initiative, University of British Columbia, Vancouver, BC, Canada"},{"name":"Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"issue":"5","key":"2021012213102245900_CIT0001","first-page":"CD009329","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2021012213102245900_CIT0002","first-page":"CD006103","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2021012213102245900_CIT0003","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ije\/dyx109","article-title":"The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective cohort study of electronic medical records","volume":"46","author":"Taylor","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2021012213102245900_CIT0004","author":"Health Canada","year":"2008"},{"key":"2021012213102245900_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2050312118777953","article-title":"Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004\u20132016","volume":"6","author":"Motooka","year":"2018","journal-title":"SAGE Open Med"},{"key":"2021012213102245900_CIT0006","author":"U.S. Food and Drug Administration"},{"issue":"10037","key":"2021012213102245900_CIT0007","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"2021012213102245900_CIT0008","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamapsychiatry.2013.678","article-title":"Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal","volume":"70","author":"Cinciripini","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"2021012213102245900_CIT0009","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1176\/appi.ajp.2013.12121599","article-title":"Varenicline, smoking cessation, and neuropsychiatric adverse events","volume":"170","author":"Gibbons","year":"2013","journal-title":"Am J Psychiatry"},{"key":"2021012213102245900_CIT0010","article-title":"Health Canada reviewing stop-smoking drug Champix (varenicline tartrate) and potential risk of heart problems in patients with heart disease.","author":"Health Canada Safety Alert","year":"2011"},{"key":"2021012213102245900_CIT0011","author":"Pfizer","year":"2009"},{"issue":"12","key":"2021012213102245900_CIT0012","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1503\/cmaj.110218","article-title":"Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis","volume":"183","author":"Singh","year":"2011","journal-title":"CMAJ"},{"issue":"2","key":"2021012213102245900_CIT0013","doi-asserted-by":"crossref","first-page":"e002849","DOI":"10.1161\/JAHA.115.002849","article-title":"Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"5","author":"Sterling","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2021012213102245900_CIT0014","article-title":"PharmaNet. BC Ministry of Health. Data Stewardship Committee (2015) Data Extract.","author":"BC Ministry of Health","year":"(2015)."},{"key":"2021012213102245900_CIT0015","author":"British Columbia Ministry of Health","year":"(2015):"},{"key":"2021012213102245900_CIT0016","author":"British Columbia Ministry of Health","year":"(2015)"},{"key":"2021012213102245900_CIT0017","author":"Canadian Institute for Health Information","year":"(2015)"},{"key":"2021012213102245900_CIT0018","author":"British Columbia Ministry of Heatlh","year":"(2015)"},{"key":"2021012213102245900_CIT0019","author":"BC Vital Statistics Agency","year":"(2015):"},{"key":"2021012213102245900_CIT0020","volume-title":"Inventory of Studies on the Accuracy of Canadian Health Administrative Databases","author":"Williams","year":"1996"},{"issue":"24","key":"2021012213102245900_CIT0021","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/sim.4780142404","article-title":"Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles","volume":"14","author":"Rawson","year":"1995","journal-title":"Stat Med"},{"issue":"8","key":"2021012213102245900_CIT0022","doi-asserted-by":"crossref","first-page":"e104519","DOI":"10.1371\/journal.pone.0104519","article-title":"Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis","volume":"9","author":"McCormick","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"2021012213102245900_CIT0023","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1161\/01.STR.0000032240.28636.BD","article-title":"Validating administrative data in stroke research","volume":"33","author":"Tirschwell","year":"2002","journal-title":"Stroke"},{"issue":"8","key":"2021012213102245900_CIT0024","doi-asserted-by":"crossref","first-page":"e0135834","DOI":"10.1371\/journal.pone.0135834","article-title":"Validity of diagnostic codes for acute stroke in administrative databases: a systematic review","volume":"10","author":"McCormick","year":"2015","journal-title":"PLoS One"},{"key":"2021012213102245900_CIT0025","doi-asserted-by":"crossref","first-page":"j4323","DOI":"10.1136\/bmj.j4323","article-title":"Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study","volume":"359","author":"Jun","year":"2017","journal-title":"BMJ"},{"issue":"7","key":"2021012213102245900_CIT0026","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/S0828-282X(10)70416-5","article-title":"Estimating the number of coronary artery bypass graft and percutaneous coronary intervention procedures in Canada: a comparison of cardiac registry and Canadian Institute for Health Information data sources","volume":"26","author":"Gurevich","year":"2010","journal-title":"Can J Cardiol"},{"key":"2021012213102245900_CIT0027","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/pds.2335","article-title":"A systematic review of validated methods for identifying suicide or suicidal ideation using administrative or claims data","volume":"21","author":"Walkup","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8 Pt 2","key":"2021012213102245900_CIT0028","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","article-title":"Estimating causal effects from large data sets using propensity scores","volume":"127","author":"Rubin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"4","key":"2021012213102245900_CIT0029","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"issue":"3","key":"2021012213102245900_CIT0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"2","key":"2021012213102245900_CIT0031","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3945\/ajcn.115.125914","article-title":"Best (but oft-forgotten) practices: propensity score methods in clinical nutrition research","volume":"104","author":"Ali","year":"2016","journal-title":"Am J Clin Nutr"},{"issue":"28","key":"2021012213102245900_CIT0032","first-page":"A4775","article-title":"Weg met oddsratio\u2019s: risicoratio\u2019s in cohortonderzoek en gerandomiseerd gecontroleerd onderzoek [Down with odds ratios: risk ratios in cohort studies and randomised clinical trials]","volume":"156","author":"Knol","year":"2012","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"10","key":"2021012213102245900_CIT0033","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/aje\/kwg074","article-title":"Estimating the relative risk in cohort studies and clinical trials of common outcomes","volume":"157","author":"McNutt","year":"2003","journal-title":"Am. J. Epidemiol"},{"issue":"5","key":"2021012213102245900_CIT0034","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jamainternmed.2018.0397","article-title":"Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial","volume":"178","author":"Benowitz","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2021012213102245900_CIT0035","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2213-2600(15)00470-1","article-title":"Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? Authors\u2019 reply","volume":"3","author":"Kotz","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2021012213102245900_CIT0036","doi-asserted-by":"crossref","DOI":"10.1111\/add.14951","article-title":"Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study","author":"Carney","year":"2020","journal-title":"Addiction"},{"key":"2021012213102245900_CIT0037","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.pmedr.2015.10.011","article-title":"Associations between smoking behaviors and financial stress among low-income smokers","volume":"2","author":"Widome","year":"2015","journal-title":"Prev Med Rep"},{"issue":"7","key":"2021012213102245900_CIT0038","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2021012213102245900_CIT0039","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12874-016-0119-1","article-title":"Head to head comparison of the propensity score and the high-dimensional propensity score matching methods","volume":"16","author":"Guertin","year":"2016","journal-title":"BMC Med Res Methodol"}],"container-title":["Nicotine &amp; Tobacco Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ntr\/advance-article-pdf\/doi\/10.1093\/ntr\/ntaa100\/33497615\/ntaa100.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ntr\/article-pdf\/23\/2\/302\/35958471\/ntaa100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ntr\/article-pdf\/23\/2\/302\/35958471\/ntaa100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T16:41:18Z","timestamp":1611420078000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ntr\/article\/23\/2\/302\/5850393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6,2]]},"published-print":{"date-parts":[[2021,1,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ntr\/ntaa100","relation":{},"ISSN":["1469-994X"],"issn-type":[{"value":"1469-994X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,6,2]]}}}